Wall Street analyst estimates for Indaptus Therapeutics, Inc. (INDP): consensus price target, buy/hold/sell recommendations and forecasts for revenue, EPS and EBITDA for the upcoming fiscal years.
Indaptus Therapeutics, Inc. is a biotechnology company operating in the pre-clinical phase, dedicated to developing a range of immunotherapeutic products for the treatment of both cancer and viral infections. The firm's lead investigational compound, Decoy20, is currently progressing through Phase I clinical trials.
Analyst Consensus
| Strong Buy | 0 |
| Buy | 2 |
| Hold | 0 |
| Sell | 0 |
| Strong Sell | 0 |
| Total analysts | 2 |
| Avg rating (1-5) | 1.00 |
Valuation Ratios
| Price / Book | 32.78 |
| EV / EBITDA | -22.52 |
| Dividend Yield | 0.00% |
Income Statement (10y)
| Year | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Cost of Revenue | $701000 | $829000 | $859000 | $854000 | 0 | 0 | 0 | 0 | 0 | 0 |
| Gross Profit | -$701000 | -$829000 | -$859000 | -$854000 | 0 | 0 | 0 | 0 | 0 | 0 |
| Research & Development | $10.1M | $24.3M | $35.4M | $26.7M | $2.7M | $2.5M | $6.3M | $7.6M | $7.3M | $9.3M |
| Selling, General & Admin | $3.1M | $4.3M | $7.1M | $7.4M | $944248 | $5.2M | $8.6M | $8.8M | $8.1M | $10.5M |
| Operating Expenses | $13.1M | $28.6M | $42.5M | $34.1M | $3.6M | $7.7M | $14.9M | $16.4M | $15.4M | $19.8M |
| Operating Income | -$13.8M | -$29.4M | -$43.3M | -$34.9M | -$3.6M | -$7.7M | -$14.9M | -$16.4M | -$15.4M | -$19.8M |
| EBITDA | -$13.1M | -$28.6M | -$42.6M | -$46.1M | -$3.6M | -$7.7M | -$14.3M | -$15.4M | -$15.0M | -$20.8M |
| Interest Expense | $16000 | $17000 | $23000 | $15000 | 0 | 0 | 0 | 0 | 0 | 0 |
| Pre-tax Income | -$13.4M | -$28.9M | -$43.4M | -$47.0M | -$3.6M | -$7.7M | -$14.3M | -$15.4M | -$15.0M | -$20.8M |
| Income Tax | 0 | $29000 | $103000 | $638000 | 0 | 0 | 0 | 0 | 0 | 0 |
| Net Income | -$13.4M | -$28.9M | -$43.5M | -$47.6M | -$3.6M | -$7.7M | -$14.3M | -$15.4M | -$15.0M | -$20.8M |
| EPS | $-2620.80 | $-3666.83 | $-3126.86 | $-3156.74 | $-206.42 | $-52.78 | $-48.54 | $-51.41 | $-44.96 | $-21.58 |
| EPS (Diluted) | $-2620.80 | $-3666.83 | $-3126.86 | $-3156.74 | $-206.42 | $-52.78 | $-48.54 | $-51.41 | $-44.96 | $-21.58 |
| Shares Outstanding (Diluted) | $5110 | $7883 | $13925 | $15078 | $17363 | $146092 | $295075 | $300037 | $334132 | $966124 |
Price
| Price | $3.21 |
| Market Cap | $364M |
| Exchange | NASDAQ |
| Country | US |
Related companies: ATXI · AZTR · GTBP · LIPO · NKGN · PBM · PTIX
Explore sector: Healthcare · Biotechnology
More sections of INDP: Overview · Financials · Valuation · Statistics · Technical · Ownership · News · Events
Discover more: Radar — undervalued stock signals · Investment Academy — learn to analyze stocks